Preclinical toxicology and pharmacology of drugs

Ended Definitive Contract Awarded Last action

Contract number
HHSN261200422002C
Awardee
Awarding agency
Obligated
$17,722,714

Award facts

Contract value 11% obligated
  • $123,646,608.46 Current, with exercised options
  • $159,319,089.46 Potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
Not on record
Set-aside
No set-aside
Competition
Full and Open Competition · 8 offers
Pricing
Cost Plus Fixed Fee
Place of performance
Chicago, IL 60616, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action 25 -$26,281
Other Administrative Action 24 -$363,628
Other Administrative Action 23 $0
Other Administrative Action 22 $0
Funding Only Action 21 -$1
Other Administrative Action 20 $0
Other Administrative Action 19 · Preclinical toxicology and pharmacology of drugs developed for cancer, aids,&aids related illnesses $0
Other Administrative Action 18 -$108,499
Funding Only Action 17 $366,840
Supplemental Agreement for work within scope 16 · Arra::yes::arra recovery act xenograft screening of new therapeutic molecules $7,000,000
Funding Only Action 15 $1,322,758
Other Administrative Action 14 $0
Funding Only Action 13 $789,637
Funding Only Action 12 $1,152,233
Funding Only Action 11 $85,000
Funding Only Action 10 $1,237,233
Other Administrative Action 9 $0
Funding Only Action 8 $2,234,648
Funding Only Action 7 $6,200
Funding Only Action 6 $32,322
Funding Only Action 5 $120,000
Funding Only Action 4 $845,236
Funding Only Action 3 $1,157,284
Funding Only Action 2 $419,286
Funding Only Action 1 $700,000
Original award $1,119,286
Show all 26

About this award

Written by GovTribe AI ·

The National Cancer Institute awarded a definitive cost-plus-fixed-fee contract to IIT Research Institute (IITRI), a non-profit contract research organization and subsidiary of the Illinois Institute of Technology, for preclinical toxicology and pharmacology services supporting drug development for cancer, AIDS, and AIDS-related illnesses. The contract, awarded on April 1, 2004, carries a ceiling value of $159.3 million with an ultimate completion date of June 30, 2016, and will be performed at IITRI's Chicago, Illinois facility. This contract was not issued under a set-aside designation.

IITRI specializes in delivering comprehensive preclinical research support to federal agencies within the National Institutes of Health, conducting extensive toxicology and pharmacology studies including dose-range finding, safety evaluations, efficacy assessments, and pharmacokinetic analyses to support investigational new drug applications. The work encompasses both GLP and non-GLP toxicology studies utilizing rodents, dogs, and mice across various therapeutic areas. As a child contract under a larger vehicle supporting the National Cancer Institute's drug development initiatives, this award leverages IITRI's established expertise in preclinical research services critical to advancing potential therapeutic candidates from discovery through clinical trial readiness.

Quick answers

Who was awarded contract HHSN261200422002C?

HHSN261200422002C was awarded to IIT Research Institute by National Cancer Institute (National Institutes of Health) on April 1, 2004.

How much is contract HHSN261200422002C worth?

The government has obligated $17,722,714 on HHSN261200422002C. Its current value, with exercised options, is $123,646,608. Its potential value, with all options, is $159,319,089.

Was contract HHSN261200422002C competed?

The extent of competition for HHSN261200422002C was full and open competition. The government received 8 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login